These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36274565)

  • 1. Using synthetic controls to estimate the population-level effects of Ontario's recently implemented overdose prevention sites and consumption and treatment services.
    Panagiotoglou D; Lim J
    Int J Drug Policy; 2022 Dec; 110():103881. PubMed ID: 36274565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic.
    Irvine MA; Kuo M; Buxton JA; Balshaw R; Otterstatter M; Macdougall L; Milloy MJ; Bharmal A; Henry B; Tyndall M; Coombs D; Gilbert M
    Addiction; 2019 Sep; 114(9):1602-1613. PubMed ID: 31166621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The associations of supervised consumption services with the rates of opioid-related mortality and morbidity outcomes at the public health unit level in Ontario (Canada): A controlled interrupted time-series analysis.
    Robinson T; Farrokhyar F; Fischer B
    Drug Alcohol Rev; 2024 Nov; 43(7):1880-1891. PubMed ID: 39104058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geographic variation in the provision of naloxone by pharmacies in Ontario, Canada: A population-based small area variation analysis.
    Antoniou T; McCormack D; Campbell T; Sutradhar R; Tadrous M; Lum-Wilson N; Leece P; Munro C; Gomes T
    Drug Alcohol Depend; 2020 Nov; 216():108238. PubMed ID: 32891910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a publicly funded pharmacy-dispensed naloxone program on fatal opioid overdose rates: A population-based study.
    Antoniou T; Men S; Tadrous M; Leece P; Munro C; Gomes T
    Drug Alcohol Depend; 2022 Jul; 236():109473. PubMed ID: 35523113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the uncertain effect of the COVID pandemic on drug overdoses.
    Moghtaderi A; Zocchi MS; Pines JM; Venkat A; Black B
    PLoS One; 2023; 18(8):e0281227. PubMed ID: 37561686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
    Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
    Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid-related emergency department visits and deaths after a harm-reduction intervention: a retrospective observational cohort time series analysis.
    Yeung MEM; Lee CH; Hartmann R; Lang E
    CMAJ Open; 2023; 11(3):E537-E545. PubMed ID: 37339791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population-based time-series analysis.
    Antoniou T; Martins D; Campbell T; Tadrous M; Munro C; Leece P; Mamdani M; Juurlink DN; Gomes T
    Addiction; 2021 Jun; 116(6):1514-1520. PubMed ID: 33207025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAEP Position Statement: Emergency department management of people with opioid use disorder.
    Koh JJ; Klaiman M; Miles I; Cook J; Kumar T; Sheikh H; Dong K; Orkin AM; Ali S; Shouldice E
    CJEM; 2020 Nov; 22(6):768-771. PubMed ID: 33028446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis.
    Walley AY; Xuan Z; Hackman HH; Quinn E; Doe-Simkins M; Sorensen-Alawad A; Ruiz S; Ozonoff A
    BMJ; 2013 Jan; 346():f174. PubMed ID: 23372174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the impact of naloxone dispensation at public health vending machines in Clark County, Nevada.
    Allen ST; O'Rourke A; Johnson JA; Cheatom C; Zhang Y; Delise B; Watkins K; Reich K; Reich R; Lockett C
    Ann Med; 2022 Dec; 54(1):2692-2700. PubMed ID: 36168975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective analysis of patterns of opioid overdose and interventions delivered at a tertiary hospital emergency department: impact of COVID-19.
    Potaka KL; Freeman R; Soo D; Nguyen NA; Sim TF; Moullin JC
    BMC Emerg Med; 2022 Apr; 22(1):62. PubMed ID: 35397487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the population-level effects of overdose prevention sites and supervised consumption sites in British Columbia, Canada: Controlled interrupted time series.
    Panagiotoglou D
    PLoS One; 2022; 17(3):e0265665. PubMed ID: 35316284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of emergency department visits for opioid overdose: a population-based study.
    Hasegawa K; Brown DF; Tsugawa Y; Camargo CA
    Mayo Clin Proc; 2014 Apr; 89(4):462-71. PubMed ID: 24629443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A statewide evaluation of seven strategies to reduce opioid overdose in North Carolina.
    Alexandridis AA; McCort A; Ringwalt CL; Sachdeva N; Sanford C; Marshall SW; Mack K; Dasgupta N
    Inj Prev; 2018 Feb; 24(1):48-54. PubMed ID: 28835443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in U.S. emergency department visits for opioid overdose, 1993-2010.
    Hasegawa K; Espinola JA; Brown DF; Camargo CA
    Pain Med; 2014 Oct; 15(10):1765-70. PubMed ID: 25139712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient characteristics associated with being offered take home naloxone in a busy, urban emergency department: a retrospective chart review.
    O'Brien DC; Dabbs D; Dong K; Veugelers PJ; Hyshka E
    BMC Health Serv Res; 2019 Sep; 19(1):632. PubMed ID: 31488142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study.
    Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Christmass M; Dunlop A; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Treloar C; Dore GJ; Grebely J;
    Int J Drug Policy; 2021 Oct; 96():103421. PubMed ID: 34452808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naloxone prescriptions following emergency department encounters for opioid use disorder, overdose, or withdrawal.
    Kilaru AS; Liu M; Gupta R; Perrone J; Delgado MK; Meisel ZF; Lowenstein M
    Am J Emerg Med; 2021 Sep; 47():154-157. PubMed ID: 33812332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.